triazoles has been researched along with thalidomide in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Lorke, D; Machemer, L | 1 |
| Kuwano, M; Ono, M | 1 |
| Libutti, SK; Zogakis, TG | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Ozawa, K | 1 |
| Ohyashiki, K | 1 |
| Tefferi, A | 1 |
| Miyazaki, Y | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Tohyama, K | 1 |
| Fraser, K | 1 |
| Altieri, M; Coleman, K; Crew, AP; Crews, CM; Dong, H; Hines, J; Lu, J; Qian, Y; Raina, K; Wang, J; Winkler, JD | 1 |
| Chaudhary, PM; Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T | 1 |
| Barbieri, CE; Beca, F; Beck, AH; Blattner, M; Bradner, JE; Buckley, DL; Buser, L; Chen, T; Chen, Y; Dai, X; Gan, W; Garraway, LA; Guo, J; Huang, J; Huang, L; Inuzuka, H; Li, X; Liu, P; Liu, S; Muthuswamy, SK; Qi, J; Rubin, MA; Shimizu, K; Vasudevan, D; Wang, L; Wang, S; Wei, W; Wild, PJ; Wong, KK; Zhang, J; Zhang, W; Zhong, Q | 1 |
| Akuffo, AA; Alontaga, AY; Ayaz, M; Beatty, MS; Becker, A; Daniel, K; Epling-Burnette, PK; Goodheart, WE; Guida, W; Gunawan, S; Hesterberg, RS; Karim, MR; Lawrence, HR; Lawrence, NJ; McDaniel, JM; Metcalf, R; Orobello, ME; Rajadhyaksha, AM; Schönbrunn, E; Yang, Y; Yoder, JA | 1 |
| Burgos, M; Esparís-Ogando, A; Galán-Moya, EM; Gómez-Juárez, M; Montero, JC; Nieto-Jimenez, C; Noblejas-López, MDM; Ocaña, A; Pandiella, A | 1 |
| Cavalcante, GC; Gu, J; He, X; Owonikoko, TK; Sun, SY; Wang, S; Yao, W; Zhang, G; Zong, D | 1 |
| Emnéus, JK; Holst, B; Lauschke, K; Meiser, I; Neubauer, JC; Rasmussen, MA; Rosenmai, AK; Schmidt, K; Taxvig, C; Vinggaard, AM | 1 |
7 review(s) available for triazoles and thalidomide
| Article | Year |
|---|---|
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured | 1997 |
General aspects of anti-angiogenesis and cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Clinical Trials as Topic; Collagen; Cyclohexanes; Endostatins; Endothelial Growth Factors; Fatty Acids, Unsaturated; Humans; Interleukin-12; Lymphokines; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Receptors, Vitronectin; RNA, Catalytic; Sesquiterpenes; Suramin; Thalidomide; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
12 other study(ies) available for triazoles and thalidomide
| Article | Year |
|---|---|
Studies of embryo toxicity in rats and rabbits.
Topics: Animals; Biphenyl Compounds; Coloring Agents; Embryo, Mammalian; Female; Fetus; Male; Pregnancy; Rabbits; Rats; Rats, Inbred Strains; Stilbenes; Thalidomide; Triazoles | 1975 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Topics: Acetanilides; Adaptor Proteins, Signal Transducing; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Heterocyclic Compounds, 3-Ring; Humans; Nuclear Proteins; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases | 2015 |
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Thalidomide; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2016 |
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Topics: Apoptosis; Azepines; Benzodiazepines; Cell Cycle Proteins; Cell Proliferation; Cullin Proteins; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; Immunoblotting; Immunoprecipitation; Male; Molecular Targeted Therapy; Nuclear Proteins; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Repressor Proteins; RNA-Binding Proteins; Thalidomide; Transcription Factors; Triazoles; Ubiquitination | 2017 |
Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Topics: Adaptor Proteins, Signal Transducing; Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Conserved Sequence; Cullin Proteins; Humans; Immunologic Factors; Lenalidomide; Ligands; Mice; Molecular Probes; Nuclear Proteins; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proteolysis; T-Lymphocytes; Thalidomide; Transcription Factors; Triazoles; Ubiquitin; Ubiquitin-Protein Ligases | 2018 |
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Dipeptides; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Proteolysis; Thalidomide; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2019 |
BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
Topics: Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Proteins; Thalidomide; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2020 |
A novel human pluripotent stem cell-based assay to predict developmental toxicity.
Topics: Biological Assay; Cell Line; Developmental Biology; Embryoid Bodies; Epoxy Compounds; Female; Humans; Male; Myocytes, Cardiac; Oxazines; Pluripotent Stem Cells; Teratogenesis; Teratogens; Thalidomide; Toxicity Tests; Triazoles; Valproic Acid; Xanthenes | 2020 |